New hope for hemophilia: study tests safer switch to fitusiran
NCT ID NCT06145373
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study looks at whether it is safe for males aged 12 and older with severe hemophilia A to switch from their current medicine (emicizumab) to a new one called fitusiran. About 20 participants will be followed for up to 28 months to monitor side effects and blood clotting. The goal is to see if fitusiran is a good option for ongoing disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital Los Angeles- Site Number : 8400005
RECRUITINGLos Angeles, California, 90027, United States
-
Investigational Site Number : 1580001
RECRUITINGTaipei, Podlaskie, 10041, Taiwan
Conditions
Explore the condition pages connected to this study.